Enclomiphene vs Clomid

Enclomiphene is the isolated trans isomer found in clomiphene citrate, which is sold as Clomid. Clomid contains both enclomiphene and zuclomiphene.

In men with secondary hypogonadism, a phase II trial found that enclomiphene increased morning serum testosterone while preserving sperm counts. However, the trial did not directly compare enclomiphene with Clomid.¹

Neither drug is FDA-approved for male hypogonadism. Before choosing either off-label treatment, your prescriber has to weigh your fertility goals, symptoms, hormone pattern, and follow-up labs.

Direct Comparison of Enclomiphene and Clomid

The main difference between enclomiphene and Clomid is isomer composition. An isomer is a form of a molecule with the same chemical formula but a different structure. Those structural differences can change how the molecule behaves in the body.

Compound	What it is	Regulatory status	What the human evidence shows	What happens to sperm production
Enclomiphene citrate	The isolated trans isomer contained within clomiphene citrate	Not approved by the Food and Drug Administration (FDA) for male hypogonadism. Use in men is off-label.	A phase II randomized clinical trial found increased morning serum testosterone, estradiol, luteinizing hormone, and follicle-stimulating hormone in men with secondary hypogonadism. Testosterone increases were similar to those seen with topical testosterone gel.1	Sperm counts were preserved in the phase II trial, while sperm counts fell in the topical testosterone group.1
Clomiphene citrate (Clomid)	A mixture of enclomiphene and zuclomiphene	FDA-approved for female ovulation induction. Use for male hypogonadism is off-label.	A serum study in men receiving long-term clomiphene confirmed exposure to both enclomiphene and zuclomiphene.3 That study did not compare testosterone outcomes against isolated enclomiphene.	The cited serum study did not measure semen outcomes, so it cannot establish how clomiphene compared with enclomiphene for sperm preservation.3

No randomized head-to-head trial in the cited evidence directly compares enclomiphene with Clomid. Claims that enclomiphene raises testosterone more, works faster, or causes fewer adverse effects than Clomid go beyond these studies.

Your physician is therefore comparing a purified isomer with a two-isomer mixture. Isomer purity offers a clear pharmacologic distinction. The available human evidence does not establish a universal clinical winner.

Mechanism Behind the Enclomiphene vs Clomid Difference

Clomiphene citrate contains enclomiphene and zuclomiphene in the same medication. Enclomiphene is the trans isomer, while zuclomiphene is the cis isomer.^2,3

A prescription for isolated enclomiphene removes zuclomiphene from the formulation. A prescription for clomiphene exposes you to both isomers. Researchers confirmed this exposure by detecting enclomiphene and zuclomiphene in the serum of men receiving clomiphene for secondary hypogonadism.³

That serum finding answers a narrow question. Both isomers enter circulation during clomiphene treatment. It does not show that one treatment produced better symptoms, testosterone levels, semen parameters, or safety outcomes.

This distinction matters when your prescriber evaluates the rationale for isolated enclomiphene. The argument rests on controlling which isomer you receive. It does not rest on proof from a direct randomized comparison with Clomid.

Human Evidence for Enclomiphene Citrate

The main human trial for enclomiphene compared it with topical testosterone gel in men with secondary hypogonadism. Secondary hypogonadism means testosterone is low because signaling from the hypothalamus or pituitary gland is low or inappropriately normal.

The phase II randomized trial measured morning serum testosterone, estradiol, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and semen parameters. LH signals the testes to produce testosterone. FSH supports sperm production.

Enclomiphene increased morning serum testosterone, estradiol, LH, and FSH. The increase in morning testosterone was similar to the increase observed with topical testosterone gel.¹ Sperm counts were conserved with enclomiphene and reduced with topical testosterone.¹

The trial supports two conclusions. Enclomiphene can increase testosterone in men with secondary hypogonadism, and it can preserve sperm production while doing so. The trial does not show that enclomiphene produces better testosterone results than Clomid.

Your diagnosis affects whether those findings apply to you. A treatment that works by increasing LH and FSH depends on the testes being able to respond to those signals. Your physician will therefore read testosterone alongside LH, FSH, symptoms, medical history, and fertility goals.

One testosterone value cannot answer the treatment question. The pattern provides more information.

Sperm Production and Exogenous Testosterone

Fertility preservation is the clearest human evidence supporting enclomiphene in this comparison. The phase II trial directly measured semen outcomes and found that sperm counts were preserved during enclomiphene treatment.¹

Topical testosterone raised morning serum testosterone to a similar degree in the trial, but sperm counts were not preserved.¹ Exogenous testosterone supplies testosterone from outside the body. That can reduce the hormonal signals involved in sperm production.

If having children is part of your plan, fertility belongs in the first treatment discussion. Your physician needs to know before prescribing hormone treatment because the medication’s effect on sperm production may change the choice.

You can read more about how exogenous testosterone works in Opt Health’s testosterone replacement therapy overview. That broader treatment has a different hormone and fertility profile from medications that stimulate endogenous testosterone production.

The enclomiphene trial did not establish that every man will maintain the same sperm count. It reported the average findings from its study population. Your baseline semen analysis and follow-up testing provide the information that applies to your care.

Isomer Findings in Mice

A chronic oral-dosing study in male mice found different effects from enclomiphene and zuclomiphene. Zuclomiphene alone was associated with changes involving Leydig cells, the epididymis, seminal vesicles, kidneys, and serum testosterone, FSH, and LH.²

Leydig cells are cells in the testes that produce testosterone. The epididymis stores and transports sperm. These findings gave researchers a biologic reason to investigate a preparation containing only enclomiphene.

In the same mouse study, isolated enclomiphene increased testosterone production without changes to testicular histology.² Histology is the microscopic examination of tissue.

This was an animal toxicology study. It does not establish that zuclomiphene causes the same organ or hormone effects in men. It also does not prove that enclomiphene is safer than Clomid in clinical use.

The mouse findings explain why isomer purity became a development goal. Human safety and treatment decisions still require human data, your medical history, and follow-up monitoring.

Evidence Limits and Industry Sponsorship

The evidence supports a narrower conclusion than many comparisons claim. Enclomiphene increased testosterone and preserved sperm counts when compared with topical testosterone gel.¹ Both clomiphene isomers were measurable in men taking Clomid.³

The studies do not establish these broader claims:

• Enclomiphene raises testosterone more than Clomid.
• Enclomiphene causes fewer adverse effects in men than Clomid.
• Clomid’s zuclomiphene content produces the mouse toxicology findings in humans.
• Either treatment will bring you to a specific testosterone concentration.
• One option works better for every form of low testosterone.

The phase II enclomiphene trial and the mouse isomer study were conducted or sponsored by Repros Therapeutics, the developer of enclomiphene. The serum study also included investigators affiliated with the development program.^1-3

Industry sponsorship does not erase a study’s findings. It does affect how much weight you can place on a small evidence base without independent replication. Your prescriber should separate measured outcomes from claims that the studies were not designed to test.

Clinical Factors Behind the Choice

A prescriber weighs diagnosis, fertility, treatment history, and laboratory response when comparing enclomiphene with Clomid. The isolated-isomer argument is only one part of that decision.

Your evaluation may include:

• The cause of low testosterone. The enclomiphene trial involved secondary hypogonadism. Its results cannot automatically be applied to every cause of low testosterone.
• Your fertility plans. If sperm production matters to you, semen testing gives your physician a baseline that testosterone alone cannot provide.
• Your LH and FSH pattern. These hormones show how the brain and pituitary are signaling the testes.
• Your prior response. Follow-up labs can show whether testosterone, estradiol, LH, and FSH moved in the intended direction.
• Your symptoms. A higher laboratory value has limited value if your energy, libido, sexual function, or other treatment goals do not improve.
• Regulatory status. Both medications are used off-label for male hypogonadism, so the prescribing decision requires clinical review and monitoring.

Human chorionic gonadotropin (hCG) is another prescription option discussed in male fertility care. It works differently by acting directly on testicular LH receptors rather than changing signaling upstream at the hypothalamic-pituitary level. A full hCG comparison falls outside the enclomiphene and Clomid evidence addressed here.

The comparison also changes if your diagnosis, fertility goals, or follow-up results change. Your physician may continue, change, or stop a treatment based on what your labs and symptoms show over time.

Laboratory Patterns and Follow-Up at Opt Health

Treatment begins with a baseline that can explain why testosterone is low. Total testosterone alone does not show whether the issue involves pituitary signaling, testicular response, estradiol, thyroid function, metabolic health, sleep, or another contributor.

At Opt Health, every lab panel is reviewed by a physician before treatment is offered. The panel includes more than 55 biomarkers, and labs are repeated every three to four months so the physician can adjust the plan based on your response.

That follow-up is especially relevant for off-label therapy. Your physician is watching the direction of several related markers and comparing them with your symptoms. One number is a data point. A hormone pattern gives the prescriber something to act on.

The Opt Take on Treatment Selection

After testing, your physician should interpret your full lab pattern alongside your symptoms, fertility goals, treatment history, and priorities. That context guides whether enclomiphene, Clomid, or another approach fits your situation. One testosterone result or product comparison cannot settle the choice.

At Opt Health, your plan is built from your numbers and goals. Your physician reviews related hormone and fertility markers together, explains the evidence limits and tradeoffs, and stays involved after treatment begins. Follow-up labs and ongoing conversations show how you are responding and whether the plan should change. The process continues through testing, understanding, treatment, retesting, and adjustment.

Get started: Begin with Opt Health, where a physician reads your labs, builds your plan, and adjusts it over the loop.

Frequently Asked Questions

This content is for informational purposes and does not replace evaluation, diagnosis, or treatment by a qualified medical professional.